SUMMARY  

• CAPLYTA is not approved for the treatment of schizoaffective disorder (SAD).
• No prospective, randomized trials have been reported to evaluate the safety and efficacy of CAPLYTA in patients with SAD.
• A case report described the use of CAPLYTA in a 27-year-old female who had treatment-resistant SAD.¹ 

Case report

• Shahab et al (2024)¹ describes a 27-year-old female with a 6-year history of bipolar type SAD who was treated with CAPLYTA. Over the course of 5 years, she had been previously treated with both oral and long-acting injectable antipsychotics, antidepressants, mood stabilizers, electroconvulsive therapy, and psychotherapy, which were partially effective or discontinued due to intolerable adverse events. She continued to experience psychotic episodes, along with residual symptoms of mood, depression, and delusions, which culminated in a suicide attempt. After confirming true treatment resistance, the patient was started on CAPLYTA 42 mg, resulting in a gradual but sustained response. She improved in fatigue and cognitive thinking, without the presence of residual delusions and hallucinations. The patient’s previous physical stressors, including weight gain and fatigue, improved. The patient was reported to be more functional, stable, and independent, with no acute episodes for more than 1 year following CAPLYTA initiation.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 11 September 2025.